Zadavotide guraxetan

Zadavotide Guraxetan (also known as Lutetium‑177 Zadavotide Guraxetan, PSMA I&T, or PNT‑2002) is a targeted radioligand therapy agent under investigation for prostate cancer treatment. It combines a small molecule that binds specifically to the prostate‑specific membrane antigen (PSMA) — that is overexpressed on many prostate cancer cells — with the radioisotope lutetium‑177. When the compound attaches to PSMA‑expressing tumor cells, lutetium‑177 emits beta radiation locally, damaging the cancer cells while minimizing effects on surrounding healthy tissue. Clinical trials (Phase I/II) are underway, exploring its safety, tolerability, and effectiveness in patients with recurrent or metastatic prostate cancer. The directory classifies it as a clinical API with a peptide source/manufacturing origin. Other names for this substance include PSMA inhibitor for imaging and therapy. Its PubChem CID is 156596528.

CAS No 2192281-54-0
Molecular Formula C63H92IN11O23
Molecular Weight 1498.4 g/mol
Synonyms (2S)-2-[[(1S)-1-carboxy-5-[[8-[[(5R)-5-carboxy-5-[[(2R)-2-[[(2R)-2-[[(4R)-4-carboxy-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]butanoyl]amino]-3-(4-hydroxy-3-iodophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]pentyl]amino]-8-oxooctanoyl]amino]pentyl]carbamoylamino]pentanedioic acid

Frequently Asked Questions